Search | Page 17 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA)

    ... Associated Drug(s):  Azacitidine Decitabine Selinexor (KPT-330) ...

    Clinical Trial last updated 08/26/2016 - 9:21am.

  2. Recent developments in myelodysplastic syndromes

    ... were approved for MDS between the years 2004 – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these ... or molecular markers have consistently predicted response to azacitidine or decitabine.  -There are several novel agents and combinations ...

    Research Review last updated 05/02/2016 - 9:16am.

  3. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be ... to have better responses to hypomethylating agents, such as azacitidine and decitabine. Splicing factor genes are mutated in about 50% ...

    Research Review last updated 05/02/2016 - 9:14am.

  4. A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

    ... to an Erythropoiesis Stimulating Agent (ESA) and/or Azacitidine (AZA) followed by a dose expansion part with an additional 30 ...

    Clinical Trial last updated 04/28/2016 - 4:14pm.

  5. Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

    ... agent (such as decitabine [Vidaza] and azacitidine [AZA]). Status:  ...

    Clinical Trial last updated 04/28/2016 - 12:21pm.

  6. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

    ... failure of treatment with a hypomethylating agent (HMA), azacitidine (AZA) or decitabine (DEC). ...

    Clinical Trial last updated 04/27/2016 - 12:49pm.

  7. Acute Myeloid Leukemia (AML)

    ... chemotherapy drugs. Drugs such as decitabine or azacitidine or hydroxyurea may be better tolerated by older patients. ...

    Topic section last updated 07/07/2016 - 3:15pm.

  8. Sexuality and Intimacy

    ... and joint pain. Hypomethlyating agents like azacitidine (Vidaza®) can cause nausea/vomiting, diarrhea, fatigue ...

    Page last updated 05/02/2016 - 10:09am.

  9. Sapacitibine shows promise for high-risk MDS patients

    ... drugs approved by the Food and Drug Administration are azacitidine (5-AZA, Vidaza®) and decitabine (Dacogen®). Both of ...

    Research Review last updated 05/02/2016 - 9:30am.

  10. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

    ... of 200 patients who were treated with Vidaza® ( azacitidine ), Dacogen® ( decitabine ), or both azacitidine and decitabine. The 76 patients in Cohort 2 underwent a stem ...

    Research Review last updated 05/02/2016 - 9:26am.